Table 3.
Levels of significance (P) of the differences between corresponding values in samples grown with and without AZA.
| TP53 | CEN17 | AML1 | SNRPN | Chromosome 17 | Chromosome 21 | |
|---|---|---|---|---|---|---|
| CON (n = 20) |
P > 0.20 | P > 0.10 | P > 0.05 | P > 0.70 | P > 0.60 | P > 0.50 |
| ADI (n = 20) |
P < 10-13 | P < 10-12 | P < 10-15 | P > 0.50 | P > 0.30 | P > 0.20 |
| PRE (n = 14) |
P < 10-11 | P < 10-9 | P < 10-6 | ----- | P > 0.10 | P > 0.40 |
CON - samples of cancer free subjects; ADI - samples of patients with hematological malignancies obtained at diagnosis; PRE - samples of patients with hematological malignancies taken prior to alloSCT; AZA - 5-azacytidine; n - Number of cases tested within each group for each locus/chromosome; SD values - columns 1-4; and aneuploidy levels - columns 4 and 5.